Search by Drug Name, NDC or Jcode
Internal Navigation
HCPCS Details
HCPC | Q5114 |
Short Description | Inj ogivri 10 mg |
Long Description | Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg |
Pricing indicator | 51 |
Coverage code | C |
ASC payment group code | |
BETOS2 code | O1E |
Action code | N |
Type of service | 1 |
Effective date | 2019-07-01 |
Date Added | 2019-07-01 |
HCPCS/NDC Cross-Walk
NDC | HCPC | Description | Drug Name | Labeler Name | HCPCS Dosage | PKG Size | PKG QTY | Bill Units | Bill Units PKG |
---|---|---|---|---|---|---|---|---|---|
67457084744 | Q5114 | Inj ogivri 10 mg | OGIVRI | MYLAN INSTITUTIONAL LLC | 10 MG | 1 | 1 | 42 | 42 |
67457099115 | Q5114 | Inj ogivri 10 mg | OGIVRI | MYLAN INSTITUTIONAL LLC | 10 MG | 1 | 1 | 15 | 15 |
HCPCS Billing Calculator
Dosage given to patient (per dose) | |
---|---|
HCPCS Dosage | 10 MG |
HCPCS/CPT Billing Units | 0.1 |
Total doses ordered | |
Billing Units | 0.1 |
Drug Details
-
Trastuzumab injection products are used with other medications or after other medications have been used to treat a certain type of breast cancer that has spread to other parts of the body. Trastuzumab injection products are also used during and after treatment with other medications to decrease the chance that a certain type of breast cancer will return. Trastuzumab injection products are also used with other medications to treat certain types of stomach cancer that have spread to other parts of the body. Trastuzumab is in a class of medications called monoclonal antibodies. It works by stopping the growth of cancer cells.